Back to Search
Start Over
SO-14 Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup.
- Source :
-
Annals of Oncology . 2023 Supplement 1, Vol. 34, pS167-S168. 2p. - Publication Year :
- 2023
- Subjects :
- *HEPATOCELLULAR carcinoma
*SORAFENIB
*AGE
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 34
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 164583744
- Full Text :
- https://doi.org/10.1016/j.annonc.2023.04.486